Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.

Nucera C, Lawler J, Parangi S.

Cancer Res. 2011 Apr 1;71(7):2417-22. doi: 10.1158/0008-5472.CAN-10-3844. Epub 2011 Mar 29. Review.

2.

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.

Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA.

Oncogene. 2011 Jul 14;30(28):3153-62. doi: 10.1038/onc.2011.44. Epub 2011 Mar 7.

3.

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S.

Oncologist. 2011;16(3):296-309. doi: 10.1634/theoncologist.2010-0317. Epub 2011 Feb 25.

4.

The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?

Nucera C, Lawler J, Hodin R, Parangi S.

Oncotarget. 2010 Dec;1(8):751-6. Review.

5.

Inhibition of mutated, activated BRAF in metastatic melanoma.

Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB.

N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.

6.

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.

Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S.

Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54. doi: 10.1073/pnas.1004934107. Epub 2010 May 24.

7.

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.

Nature. 2010 Mar 18;464(7287):427-30. doi: 10.1038/nature08902.

8.

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R.

Cell. 2010 Jan 22;140(2):209-21. doi: 10.1016/j.cell.2009.12.040.

9.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
10.

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6. doi: 10.1073/pnas.0905833106. Epub 2009 Nov 13.

11.

Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G.

J Clin Endocrinol Metab. 2010 Jan;95(1):450-5. doi: 10.1210/jc.2009-0373. Epub 2009 Oct 30.

PMID:
19880792
12.

The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.

Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.

Cancer Res. 2009 Nov 1;69(21):8317-25. doi: 10.1158/0008-5472.CAN-09-1248. Epub 2009 Oct 27.

13.

A novel orthotopic mouse model of human anaplastic thyroid carcinoma.

Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S.

Thyroid. 2009 Oct;19(10):1077-84. doi: 10.1089/thy.2009.0055.

14.

Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.

Packer LM, East P, Reis-Filho JS, Marais R.

Pigment Cell Melanoma Res. 2009 Dec;22(6):785-98. doi: 10.1111/j.1755-148X.2009.00618.x. Epub 2009 Aug 4.

PMID:
19682280
15.

Anaplastic thyroid cancer manifesting as new-onset Horner syndrome.

Broome JT, Gauger PG, Miller BS, Doherty GM.

Endocr Pract. 2009 Sep-Oct;15(6):563-6. doi: 10.4158/EP09106.CRR. Review.

PMID:
19491063
16.

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA.

Cancer Res. 2009 Jun 1;69(11):4885-93. doi: 10.1158/0008-5472.CAN-09-0727.

17.

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R.

J Clin Oncol. 2009 Jun 20;27(18):2977-82. doi: 10.1200/JCO.2008.20.1426. Epub 2009 May 4.

18.

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

Nucera C, Goldfarb M, Hodin R, Parangi S.

Biochim Biophys Acta. 2009 Apr;1795(2):152-61. doi: 10.1016/j.bbcan.2009.01.003. Epub 2009 Jan 31. Review.

19.

Phase II trial of sorafenib in metastatic thyroid cancer.

Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH.

J Clin Oncol. 2009 Apr 1;27(10):1675-84. doi: 10.1200/JCO.2008.18.2717. Epub 2009 Mar 2.

20.

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Smallridge RC, Marlow LA, Copland JA.

Endocr Relat Cancer. 2009 Mar;16(1):17-44. doi: 10.1677/ERC-08-0154. Epub 2008 Nov 5. Review.

Supplemental Content

Support Center